Comparing Journey Medical (DERM) & Its Competitors

Journey Medical (NASDAQ:DERM – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Journey Medical to similar businesses based on the strength of its profitability, risk, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Institutional & Insider Ownership

7.2% of Journey Medical shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 14.5% of Journey Medical shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Journey Medical and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Journey Medical 2 0 2 0 2.00
Journey Medical Competitors 7845 13797 25812 1039 2.41

Journey Medical currently has a consensus price target of $13.00, indicating a potential upside of 213.63%. As a group, “Pharmaceuticals” companies have a potential upside of 23.61%. Given Journey Medical’s higher probable upside, research analysts plainly believe Journey Medical is more favorable than its peers.

Volatility & Risk

Journey Medical has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Comparatively, Journey Medical’s peers have a beta of -0.04, indicating that their average share price is 104% less volatile than the S&P 500.

Earnings and Valuation

This table compares Journey Medical and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Journey Medical $61.86 million -$11.43 million -23.03
Journey Medical Competitors $18.60 billion $3.23 billion 560.44

Journey Medical’s peers have higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Journey Medical and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Journey Medical -7.34% -16.07% -5.26%
Journey Medical Competitors -2,398.26% -203.62% -15.08%

Summary

Journey Medical peers beat Journey Medical on 7 of the 13 factors compared.

About Journey Medical

(Get Free Report)

Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and marketing prescription treatments for dermatological conditions. Founded in 2014 and based in Scottsdale, Arizona, the company primarily serves the U.S. market. Its portfolio includes treatments for conditions such as acne, rosacea, excessive underarm sweating and fungal skin infections. Products include Amzeeq and Zilxi, topical minocycline therapies; Qbrexza, a topical treatment for primary axillary hyperhidrosis; and the oral rosacea treatment Emrosi.

Receive News & Ratings for Journey Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Journey Medical and related companies with MarketBeat.com's FREE daily email newsletter.